Современные методы диагностики ограниченной склеродермии

Литература:
1. Kreuter A, Krieg T, Worm M, et al. German guidelines for the diagnosis and therapy of localized scleroderma; JDDG 1610-0379/2016/1402: 199-216
2. Marsol I. Update on the classification and treatment of localized scleroderma. Actas Dermo-Sifiliograficas (English edition) 2013; 104 (8): 654-666
3. Jackson C, Maibach H. Localized scleroderma variants: pharmacologic implications. J Dermatol Treat 2014; 25 (6): 529-531
4.Ferguson I, Weiser P, TorokK.ACase Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide. TORJ 2015; 9: 30
5. Kreuter A. Localized scleroderma. Dermatologic therapy 2012; 25 (2): 135-147
6. Careta M, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol 2015; 90 (1): 62-73
7. Brady S, Shapiro L, Mousa S. Current and future direction in the management of scleroderma. Arch Dermatol Res 2016; Published online 30 April 2016
8. Бакулев А.Л., Галкина E.H., Каракаева А.В. Литвиненко М.В. Случай локализованной буллезной склеродермии. Вестник дерматологии и венерологии 2016; (3): 97-101
9. Zulian F. Juvenile Localized Scleroderma. Scleroderma 2012;9:85-92
10. Кубанова A.A., Кубанов A.A., Волнухин В.А. Федеральные клинические рекомендации. Дерматовенерология, 2015. Болезни кожи. Инфекции, передаваемые половым путём. Москва, 2016; с. 260-274
11. Kurzinski К, Torok К. Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine 2011; 55(2): 157-164
12. Fett N. Scleroderma: nomenclature, etiology pathogenesis, prognosis, and treatments: facts and controversies. Clinics in dermatology 2013; 31 (4): 432-437
13. Succaria F, Kurban M, Kibbi A, et al. Clinicopathological study of 81 cases of localized and systemic scleroderma. EADV 2013; 27 (2): 191-196
14. Zulian F, Trainito S, Belloni-Fortina A. Localized Scleroderma of the Face. Skin Manifestations in Rheumatic Disease 2014; 22: 175-183
15. Hunzelmann N, Horneff G, Krieg T. Skin Manifestations of Localized Scleroderma (LS). Skin Manifestations in Rheumatic Disease 2014; 21: 165-173
16. Cutolo M, Herrick A, Distler O, et al. Nailfold videocapillaroscopy and other predictive factors associated with new digital ulcers in systemic sclerosis. ANN RHEUM DIS 2013; 72: 146-147
17. Cutolo M, Zampogna G, Vremis L, et al. Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. The Journal of Rheumatology 2013; 40 (1): 40-45
18. Cutolo M, Sulli A, Smith V. How to perform and interpret capillaroscopy? Best practice & research. Clinical rheumatology 2013; 27 (2): 237-248
19. Sulli A, Pizzorni C, Smith V, et al. Timing of transition between capillaroscopic patterns in systemic sclerosis. Arthritis Rheum 2012; 64 (3): 821-825
20. Rosato E, Giovannetti A, Pisarri S, etal. Skin perfusion of fingers shows a negative correlation with capillaroscopic damage in patients with systemic sclerosis. The Journal of rheumatology 2013; 40(1): 98-99
21. Rosato E, Rossi C, Molinaro I, et al. Laser Doppler perfusion imaging in systemic sclerosis impaired response to cold stimulation involves digits and hand dorsum. Rheumatology 2011; 50 (9): 1654-8
22. Rosato E, Molinaro I, Rossi C, et al. The combination of laser Doppler perfusion imaging and photoplethysmography is useful in the characterization of scleroderma and primary Raynaud's phenomenon. Scand J Rheumatol 2011; 40 (4): 292-8
23. Chapin R, Hant F. Imaging of scleroderma. Rheumatic Disease Clinics of North America 2013; 39 (3): 515-546
24. Schanz S, Fierlbeck G, Ulmer A, Schmalzing M, et al. Localized scleroderma: MR findings and clinical features. Radiology 2011; 260 (3): 817-824
25. Li S, Fuhlbrigge R, Dedeoglu F, et al. Developing juvenile localized scleroderma (jLS) consensus treatment regimens for comparative effectiveness studies. PReS 2012; 10 (1): A68
26. Arkachaisri T, Vilaiyuk S, Li S, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. The Journal of rheumatology 2009; 36 (12): 2819-2829
27. Hawley D, Pain C, Baildam E, et al. United Kingdom survey of current management of juvenile localized scleroderma. Rheumatology 2014; 53 (10): 1849-1854
28. Kelsey С, Torok K. The localized scleroderma cutaneous assessment tool responsiveness to change in a pediatric clinical population. J Am Acad Dermatol 2013; 69 (2): 214-20
29. Avouac J, Fransen J, Walker U, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: Results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011; 70 (3): 476-481
30. Garcia R. Correlation of clinical tools to determine activity of localized scleroderma in pediatric patients 2015
31. Poff S, el al. Durometry as an outcome measure in juvenile localized scleroderma; British Journal of Dermatology 2016; 174:228-230
32. Buense R, Duarte I, Bouer M. Localized scleroderma: assessment of the therapeutic response to phototherapy. Anais brasileiros de dermatologia 2012; 87 (1): 63-69
33. Su O, Onsun N, Onay H, Erdemoglu Y, et al. Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma. ISD 2011; 50 (8): 1006-1013
34. Porta F, Kaloudi O, Garzitto A, et al. High frequency ultrasound can detect improvement of lesions in juvenile localized scleroderma. Modern Rheumatology 2014; 24 (5): 869-873
35. Li S, Liebling M, Haines K, et al. Initial evaluation of an ultrasound measure for assessing the activity of skin lesions in juvenile localized scleroderma. AC&R 2011; 63 (5): 735-742
36. Shalaby S, Bosseila M, Fawzy M, et al. Targeted Medium Dose UVA-1 Phototherapy for the Treatment of Localized Scleroderma in the Skin of Color: Pros and Cons. WJMS 2015; 12(3): 263-267.